TP53 and oropharynx cancer: The mutation was detected in 46.2% of oral cavity tumours and in 60% of oropharyngeal cancer in oral rinses, while in plasma, the TP53 mutation was detected in 8% of samples only (n = 3, two tumours were located in the larynx, and one case exhibited the tumour in multiple sites without further specification).